Concomitant alpha- and gamma-sarcoglycan deficiencies in a Turkish boy with a novel deletion in the alpha-sarcoglycan gene.

Limb-girdle muscular dystrophy type 2D (LGMD-2D) is caused by autosomal recessive defects in the alpha-sarcoglycan gene located on chromosome 17q21. In this study, we present a child with alpha-sarcoglycanopathy and describe a novel deletion in the alpha-sarcoglycan gene. A 5-year-old boy had a very high serum creatinine phosphokinase level, which was determined incidentally, and a negative molecular test for the dystrophin gene. Muscle biopsy showed dystrophic features. Immunohistochemistry showed that there was diminished expression of alpha- and gamma-sarcoglycans. DNA analysis revealed a novel 7 bp homozygous deletion in exon 3 of the alpha-sarcoglycan gene. His parents were consanguineous heterozygous carriers of the same deletion. We believe this is the first confirmed case of primary alpha-sarcoglycanopathy with a novel deletion in Turkey. In addition, this study demonstrated that both muscle biopsy and DNA analysis remain important methods for the differential diagnosis of muscular dystrophies because dystrophinopathies and sarcoglycanopathies are so similar.

1. Introduction

Limb girdle muscular dystrophy type 2D (LGMD-2D) is an autosomal recessive muscular disease caused by genetic defects in sarcolemmal alpha sarcoglycan (α-SGC) glycoprotein. Alpha-SGC or adhalin, one of the four sarcoglycans (SGCs), is essential for membrane integrity during muscle contraction and provides a scaffold for important signaling molecules [1-3]. Alpha-SGC is encoded by the sarcoglycan alpha gene (SGCA) located on chromosome 17q21 [1, 4]. LGMD-2D predominantly affects proximal muscles around the scapular and the pelvic girdles. LGMD-2D has a very heterogeneous phenotype. The age of onset, rate of progression, and the severity of disease can vary between and also within affected families. The most clinically severe course is generally observed when the sarcolemmal α-SGC is totally absent whereas milder phenotypes are observed when residual proteins are present [1-4]. Interestingly, a mutation in any SGC gene can lead to a reduction or absence of the other SGCs [4-7]. It was previously reported that the SGCA gene must be evaluated first if there is a concomitant absence of α-SGC and gamma- (γ-) SGC [4].

The differential diagnosis for LGMD-2D includes Duchenne and Becker muscular dystrophies (DMD/BMD) and it is impossible to reach a diagnosis on clinical grounds alone. Therefore, immunohistochemical staining of a muscle biopsy and molecular genetic analysis are mandatory for the correct diagnosis [3, 5, 8, 9]. In this report, the patient's genotype was a previously unknown 7 bp deletion in exon 3. This finding adds to the growing spectrum of mutations in the alpha-sarcoglycan gene. Finally, we also discuss important considerations in the differential diagnosis of the muscular dystrophies.

2. Case Report

A 5-year-old boy had second degree consanguineous parents from Turkey without an ancestral history of neuromuscular disorders. There were no complications during pregnancy, and antenatal signs of muscular disorders such as polyhydramnios and reduced fetal movements were not noted. Cognitive and motor development was normal. At the time of presentation, his previously undetected mild muscle weakness was predominantly proximal. Deep tendon reflexes were present and he had no contractures. He was walking normally but he had mild difficulty when climbing stairs and running. Pulmonary function tests were normal. His creatinine phosphokinase (CPK) levels were between 9000 and 15000 units per liter (normal < 250 U/L), and there were myopathic changes on electromyography. Because of the very high CPK level, muscular dystrophy was suspected and, after informed consent, samples were obtained for histopathology, immunohistochemistry, and molecular genetics testing.

A muscle biopsy specimen from the left gastrocnemius muscle of the patient was frozen in isopentane that was precooled to −160°C in liquid nitrogen. Cryosections were immunostained for dystrophin using a polyclonal antibody (Neomarkers), with a monoclonal spectrin antibody (Novocastra) as a control. A neonatal myosin heavy chain (Neonatal myosin, Novocastra) antibody was used for the identification of pathological immature myofibers. SGCs were detected with anti-α-, -β-, -δ-, and -γ-SGC antibodies (Novocastra).

Peripheral blood specimens were collected from the proband and parents. Genomic DNA was extracted from whole blood using a commercial DNA extraction kit (QiaGen, USA) following the standard manufacturer's protocol. The concentration of sample DNA was determined by a NanoDrop spectrophotometer (NanoDrop Technologies, Wilmington, DE). The exon regions and flanking short intronic sequences of the SGCA gene were amplified using polymerase chain reaction (PCR), followed by direct sequencing of the PCR products (ABI, US) (NCBI Reference Sequence: NG_008889.1). Hitherto reported genetic abnormalities in LGMD-2D are listed in Table 1.

Table 1

Nucleotide and amino acid sequences of α-SGC gene.

11

ATGMet

GCTAla

GAGGlu

ACAThr

CTCLeu

TTCPhe

TGGTrp

ACTThr

CCTPro

CTCLeu

CTCLeu

GTGVal

GTTVal

CTCLeu

CTGLeu

4616

GCAAla

GGGGly

CTGLeu

GGGGly

GACAsp

ACCThr

GAGGlu

GCCAla

CAGGln

CAGGln

ACCThr

ACGThr

CTALeu

CACHis

CCA Pro#

9131

CTT Leu#

GTGVal

GGCGly

CGT Arg#

GTCVal

TTTPhe

GTGVal

CACHis

ACCThr

TTGLeu

GACAsp

CATHis

GAGGlu

ACGThr

TTTPhe

13646

CTGLeu

AGCSer

CTTLeu

CCTPro

GAGGlu

CATHis

GTCVal

GCT Ala#

GTCVal

CCAPro

CCCPro

GCTAla

GTCVal

CACHis

ATCIle

18161

ACCThr

TAC Tyr#

CACHis

GCCAla

CACHis

CTCLeu

CAGGln

GGA Gly#

CACHis

CCAPro

GACAsp

CTGLeu

CCCPro

CGG Arg#

TGGTrp

22676

CTCLeu

CGC Arg#

TAC  Tyr##

ACC  Thr##

CAG Gln##

CGC Arg#

AGCSer

CCCPro

CACHis

CACHis

CCTPro

GGCGly

TTCPhe

CTC Leu#

TAC Tyr#

27191

GGC Gly#

TCTSer

GCC Ala#

ACCThr

CCAPro

GAAGlu

GAT Asp#

CGT Arg#

GGGGly

CTCLeu

CAGGln

GTCVal

ATT Ile#

GAGGlu

GTCVal

316106

ACAThr

GCCAla

TACTyr

AATAsn

CGG Arg#

GACAsp

AGCSer

TTTPhe

GATAsp

ACCThr

ACTThr

CGGArg

CAGGln

AGGArg

CTGLeu

361121

GTGVal

CTGLeu

GAGGlu

ATT Ile#

GGGGly

GACAsp

CCAPro

GAAGlu

GGCGly

CCCPro

CTGLeu

CTGLeu

CCAPro

TACTyr

CAAGln

406136

GCCAla

GAG Glu#

TTCPhe

CTG Leu#

GTGVal

CGC Arg#

AGCSer

CACHis

GATAsp

GCGAla

GAGGlu

GAGGlu

GTGVal

CTGLeu

CCCPro

451151

TCASer

ACAThr

CCTPro

GCCAla

AGCSer

CGCArg

TTCPhe

CTC Leu#

TCASer

GCCAla

TTGLeu

GGGGly

GGAGly

CTCLeu

TGGTrp

496166

GAGGlu

CCCPro

GGAGly

GAGGlu

CTTLeu

CAGGln

CTGLeu

CTC Leu#

AACAsn

GTC Val#

ACCThr

TCTSer

GCCAla

TTGLeu

GACAsp

541181

CGT Arg#

GGGGly

GGCGly

CGTArg

GTCVal

CCCPro

CTTLeu

CCCPro

ATTIle

GAGGlu

GGCGly

CGAArg

AAALys

GAAGlu

GGG Gly#

586196

GTA Val#

TACTyr

ATTIle

AAGLys

GTGVal

GGTGly

TCTSer

GCCAla

TCASer

CCT Pro#

TTTPhe

TCTSer

ACT Thr#

TGCCys

CTGLeu

631211

AAGLys

ATGMet

GTGVal

GCAAla

TCC Ser#

CCCPro

GATAsp

AGCSer

CACHis

GCCAla

CGC Arg#

TGTCys

GCCAla

CAG Gln#

GGCGly

676226

CAGGln

CCT Pro#

CCA Pro#

CTTLeu

CTGLeu

TCTSer

TGC Cys#

TACTyr

GACAsp

ACCThr

TTGLeu

GCAAla

CCC Pro#

CACHis

TTCPhe

721241

CGCArg

GTT Val#

GACAsp

TGGTrp

TGCCys

AATAsn

GTG Val#

ACCThr

CTGLeu

GTGVal

GATAsp

AAGLys

TCASer

GTGVal

CCGPro

766256

GAGGlu

CCTPro

GCAAla

GATAsp

GAGGlu

GTGVal

CCC Pro#

ACCThr

CCAPro

GGTGly

GATAsp

GGGGly

ATCIle

CTGLeu

GAGGlu

811271

CATHis

GAC Asp#

CCGPro

TTCPhe

TTCPhe

TGCCys

CCAPro

CCCPro

ACTThr

GAGGlu

GCCAla

CCAPro

GACAsp

CGT Arg#

GACAsp

856286

TTCPhe

TTGLeu

GTGVal

GATAsp

GCTAla

CTGLeu

GTCVal

ACCThr

CTCLeu

CTGLeu

GTGVal

CCCPro

CTGLeu

CTGLeu

GTGVal

901301

GCCAla

CTGLeu

CTTLeu

CTCLeu

ACCThr

TTGLeu

CTGLeu

CTGLeu

GCCAla

TATTyr

GTCVal

ATG Met#

TGCCys

TGCCys

CGGArg

946316

CGGArg

GAGGlu

GGAGly

AGGArg

CTGLeu

AAGLys

AGAArg

GACAsp

CTGLeu

GCTAla

ACCThr

TCCSer

GACAsp

ATCIle

CAGGln

991331

ATGMet

GTCVal

CACHis

CACHis

TGCCys

ACCThr

ATCIle

CACHis

GGGGly

AACAsn

ACAThr

GAGGlu

GAGGlu

CTGLeu

CGGArg

1036346

CAGGln

ATGMet

GCGAla

GCCAla

AGCSer

CGCArg

GAGGlu

GTGVal

CCCPro

CGGArg

CCAPro

CTCLeu

TCCSer

ACCThr

CTGLeu

1081361

CCCPro

ATGMet

TTCPhe

AATAsn

GTGVal

CACHis

ACAThr

GGTGly

GAGGlu

CGGArg

CTGLeu

CCTPro

CCCPro

CGCArg

GTGVal

1126376

GACAsp

AGCSer

GCCAla

CAGGln

GTGVal

CCCPro

CTCLeu

ATTIle

CTGLeu

GACAsp

CAGGln

CACHis

TGATer

*Note the previously determined missense mutations marked with #. The present deletion was marked with ## and bold letters.

3. Results

The muscle biopsy showed dystrophic changes like contraction, regeneration (Figure 1), degeneration, necrosis, nuclear internalization, and fibrosis. In addition, many pathological immature myofibers were visualized using the neonatal myosin staining (Figure 2). Based on immunostaining, dystrophin and spectrin expressions were normal. Except for isolated deficient fibers, beta (β) sarcoglycan and delta (δ) sarcoglycan were present at normal levels, whereas α-SGC and γ-SGC were diffusely absent (Figure 3).

Figure 1

Differences in the size and shape of myofibers as well as regeneration (HEx 200).

Figure 2

Immature pathological fibers visualized with anti-neonatal myosin antibody staining (DABx 100).

Figure 3

Diffuse absence of sarcolemmal α-SGC (a) and γ-SGC (d) expression and normal β-SGC (b) and δ-SGC (c) expression (DABx 200).

Based on analysis of the proband, we have identified a previously undetermined homozygous 7 bp deletion in exon 3 (Figure 4). A similar heterozygous deletion was found in both parents (Figures 5 and 6). Location of this deletion was also indicated in Table 1. In addition, there were no abnormalities in the dystrophin gene and the other sarcoglycan genes (SGCB, SGCD, and SGCG) in the patient and his parents.

Figure 4

Proband exon 3 homozygous del TACACCC site.

Figure 5

Maternal heterozygous del TACACCC site.

Figure 6

Paternal heterozygous del TACACCC site.

4. Discussion

Human SGCA cDNA from a human skeletal muscle library was isolated and sequenced in 1993. This gene consisted of 10 exons. The protein product of SGCA gene consisted of 387 amino acids with an extracellular N-terminus, a transmembrane domain, and an intracellular C-terminus. Northern blot analysis showed that human adhalin mRNA was expressed at the highest levels in skeletal muscle. It was also expressed in cardiac muscle and in the lung, but at much lower levels. On the contrary, adhalin mRNA was not detected in the brain. It was also reported that the adhalin mRNA from cardiac muscle was shorter relative to skeletal muscle and that the base sequence encoding the transmembrane domain was absent. It is known that LGMD-2D primarily affects skeletal muscles while brain and peripheral nerve functions are largely preserved. Briefly, the less severe cardiac dysfunction and lack of mental retardation in patients with LGMD-2D may be explained by the lower expression of α-SGC in cardiac muscle and the absence of adhalin expression in the brain [1, 3, 10]. In the patient described in this report, we did not find clinical evidence of cardiac involvement, decreased intellectual capacity, or denervation (as demonstrated by electromyography). The course of the disease in this case suggests that this novel deletion may cause a milder phenotype of LGMD-2D despite the diffuse absence of α-SGC and γ-SGC.

Immunohistochemical analysis of sarcolemmal proteins in muscle biopsies like dystrophin, SGCs, merosin, and dysferlin is an important part of the diagnostic evaluation of patients with muscular dystrophy. Reduced or absent sarcolemmal expression of one of the 4 SGCs can be found in patients with any type of LGMDs and also in patients with dystrophinopathies. It has previously been suggested that different patterns of SGC expression could predict the primary genetic defect and that genetic analysis could be directed by these patterns [5-8]. However, Klinge et al. [9] reported that residual SGC expression could be highly variable and an accurate prediction of the genotype could not be achieved. Babameto-Laku et al. [4] also determined that the concomitant absence of α-SGC and γ-SGC expression was caused by defects in the SGCA gene. Therefore, they recommended using antibodies against all four SGCs for immunoanalysis of skeletal muscle sections. Similarly, a concomitant reduction in dystrophin and any of the SGCs may illustrate the importance of considering coexisting dystrophinopathies in patients with sarcoglycan-deficient LGMD [9-13]. For this reason, it is not easy to decide whether the disease is a dystrophinopathy with defective expressions of SGCs or a LGMD with defective expression of dystrophin. However, in the patient described in this report, dystrophinopathies, such as DMD and BMD, were ruled out because the expression of sarcolemmal dystrophin was diffusely present and molecular tests for dystrophin gene were normal.

At present, more than 70 mutations have been reported in the SGCA gene that cause changes in the α-SGC glycoprotein. Approximately a two-thirds of mutations are missense mutations that generate a complete protein with a single residue substitution, whereas other mutations like nucleotide replacements, duplications, deletions, or insertions produce truncated, incomplete, or anomalous proteins. Almost all missense mutations map to the extracellular domain which is a critical region for the organization of SGCs and their association with dystroglycan. Only a single missense mutation maps to the intracellular domain and causes LGMD-2D in homozygous cases. Similarly, two mutations caused by deletions generate a normal extracellular portion of α-SGC and truncated intracellular tails. At present, there is no data about the intracellular tail of the α-SGC protein and its function [1, 10–14]. In the family described in this report, we discovered a novel deletion in the TACACCC site of exon 3 that would cause a frame-shift mutation. The past literature highlights that the prediction of pathological consequences associated with different mutations of SGCA gene is very complex. It is not clear whether this novel deletion generates a severe disease phenotype or whether it also has additional, undetermined consequences.

Patients with any of the LGMDs may be clinically indistinguishable from those with the primary dystrophinopathies. It is likely that the prevalence of LGMD is underestimated and a number of male patients are incorrectly diagnosed with DMD or BMD [13]. A definitive diagnosis rests on performing the appropriate immunohistochemical examination as well as doing a molecular analysis. A normal dystrophin staining pattern should be seen as well as an autosomal recessive mode of inheritance. In contrast, the patients with dystrophinopathies may show variable findings from a normal to a regional absence or a mosaic pattern of sarcolemmal staining with anti-SGCs antibodies which correspond to an abnormal organization of the cell-membrane-associated dystrophin glycoprotein complex. Therefore, it is necessary to perform a careful examination of the immunohistochemical staining as well as a genetic study in order to make the correct diagnosis.

In summary, this report describes a novel deletion that adds to the growing list of defects associated with LGMD-2D and further emphasizes the importance of systematic analysis of all related genes, instead of limiting the analysis to the one SGC gene that is hypothesized to be the cause of the abnormalities. In this study, we also highlight the complexity of staining patterns associated with sarcolemmal proteins and the importance of careful analysis of this staining pattern in order to narrow the differential diagnosis of muscular dystrophies.